A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection

In this commentary, we make a case that the mechanism of COVID pathogenesis is related to virus-induced endothelial injury resulting in platelet activation and the formation of microthrombi both systemically and in cardiac and pulmnonary circulation which result in major causes of COVID morbidity an...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2022-08, Vol.30 (4), p.1475-1476
Main Authors: Lichtenberger, Lenard M., Szabo, Sandor
Format: Article
Language:English
Subjects:
Allergology
Aspirin - pharmacology
Aspirin - therapeutic use
Biomedical and Life Sciences
Biomedicine
Blood Platelets
Commentary
COVID-19 Drug Treatment
Dermatology
Gastroenterology
Humans
Immunology
Pharmacology/Toxicology
Platelet Activation
Retrospective Studies
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this commentary, we make a case that the mechanism of COVID pathogenesis is related to virus-induced endothelial injury resulting in platelet activation and the formation of microthrombi both systemically and in cardiac and pulmnonary circulation which result in major causes of COVID morbidity and mortality. Aspirin by virtue of its irreversible inhibition of platelet COX-1, should reverse these platelet-induced pathogenic changes associated with COVID infection for the 6–9 day lifetime of the platelet. We also cite recent findings of a retrospective analysis that supports the use of low-dose (81 mg) aspirin to treat the symptoms associated with the early stages of COVID infection.
ISSN:0925-4692
1568-5608
1568-5608
DOI:10.1007/s10787-022-01015-w